Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Non-Current Assets: 2011-2025

Historic Other Non-Current Assets for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $8.8 million.

  • Adma Biologics' Other Non-Current Assets rose 51.19% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 51.19%. This contributed to the annual value of $5.7 million for FY2024, which is 21.13% up from last year.
  • Adma Biologics' Other Non-Current Assets amounted to $8.8 million in Q3 2025, which was down 2.92% from $9.1 million recorded in Q2 2025.
  • Adma Biologics' 5-year Other Non-Current Assets high stood at $9.1 million for Q2 2025, and its period low was $2.2 million during Q1 2021.
  • For the 3-year period, Adma Biologics' Other Non-Current Assets averaged around $6.5 million, with its median value being $5.9 million (2024).
  • Over the last 5 years, Adma Biologics' Other Non-Current Assets had its largest YoY gain of 93.04% in 2021, and its largest YoY loss of 35.85% in 2021.
  • Over the past 5 years, Adma Biologics' Other Non-Current Assets (Quarterly) stood at $4.1 million in 2021, then increased by 17.27% to $4.8 million in 2022, then dropped by 2.10% to $4.7 million in 2023, then increased by 21.13% to $5.7 million in 2024, then skyrocketed by 51.19% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $9.1 million for Q2 2025, and $8.2 million during Q1 2025.